This website uses cookies. By continuing you are agreeing to our privacy policy.

Robert Guzy, M.D., Ph.D.

Research Awards Nationwide Recipient (2017-2018)

University of Chicago
Growth Factor May Be Helpful in Treating Pulmonary Fibrosis
Dalsemer Grant
Funded by the American Lung Association of the Upper Midwest

Idiopathic pulmonary fibrosis (IPF) causes progressive scarring of the lungs, severe breathlessness, and too little oxygen. The cause of IPF is unknown. Despite current FDA-approved antifibrotic therapies, overall survival is just 3-5 years after diagnosis. Substances called Fibroblast Growth Factors (FGFs) have been implicated in pulmonary fibrosis, but their exact contribution is unclear. Our initial research suggests that FGF2 administration may decrease pulmonary fibrosis severity. We plan to define the mechanism by which FGF2 decreases pulmonary fibrosis, and determine its potential for therapeutic use.

Update: We have found that treating mice with FGF2 significantly decreases pulmonary fibrosis, and decreases the number of activated fibroblasts (the principal active cells of connective tissue) in response to bleomycin treatment. This suggests that FGF2 may be of therapeutic benefit in pulmonary fibrosis. During the coming year we will explore the antifibrotic mechanisms of FGF2 in lung fibroblasts in animal and cell culture models. We will also determine whether alterations in FGF2 signaling are present in lung fibroblasts isolated from patients with IPF.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.